Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: An analysis of the European Group for Blood and Marrow Transplantation
Blood, Volume 114, No. 10, Year 2009
Notification
URL copied to clipboard!
Description
Ninety-one children and adolescents 18 years or younger after allogeneic hematopoietic stem cell transplantation (HSCT) for relapsed or refractory Hodgkin lymphoma (HL) were analyzed. Fifty-one patients received reduced intensity conditioning (RIC); 40 patients received myeloablative conditioning (MAC). Nonrelapse mortality (NRM) at 1 year was 21% (± 4%), with comparable results after RIC or MAC. Probabilities of relapse at 2 and 5 years were 36% (± 5%) and 44%(± 6%), respectively. RIC was associated with an increased relapse risk compared with MAC; most apparent beginning 9 months after HSCT (P = .01). Progression-free survival (PFS) was 40% (± 6%) and 30% (± 6%) and overall survival (OS) was 54% (± 6%) and 45% (± 6%) at 2 and 5 years, respectively. Disease status at HSCT was predictive of PFS in multivariate analysis (P < .001). Beyond 9 months, PFS after RIC was lower compared with MAC (P = .02). Graft-versus-host disease did not affect relapse rate and PFS. In conclusion, children and adolescents with recurring HL show reasonable results with allogeneic HSCT. Especially patients allografted in recent years with good performance status and chemosensitive disease show highly encouraging results (PFS: 60% ± 27%, OS: 83% ± 15% at 3 years). Because relapse remains the major cause of treatment failure, additional efforts to improve disease control are necessary. © 2009 by The American Society of Hematology.
Authors & Co-Authors
Claviez, Alexander
Germany, Kiel
Universitätsklinikum Schleswig-holstein Campus Kiel
Canals, Carmen S.
Spain, Barcelona
Hospital de la Santa Creu I Sant Pau
Dierickx, Daan
Belgium, Leuven
Ku Leuven– University Hospital Leuven
Stein, Jerry
Israel, Petah Tiqwa
Schneider Childrens Medical Center Israel
Badell, Isabel S.
Spain, Barcelona
Hospital de la Santa Creu I Sant Pau
Pession, Andrea
Italy, Bologna
Alma Mater Studiorum Università Di Bologna
MacKinnon, Stephen
United Kingdom, London
The Royal Free Hospital
Slavin, Shimon
Israel, Jerusalem
Hadassah University Medical Centre
Dalle, Jean Hugues H.
France, Paris
Hôpital Robert-debré Ap-hp
Chacón, Manuel Jurado
Spain, Granada
Complejo Hospitalario Universitario de Granada
Sarhan, Mahmoud M.
Jordan, Amman
King Hussein Cancer Centre
Wynn, Robert Francis
United Kingdom, Manchester
Royal Manchester Children's Hospital
Suttorp, Meinolf
Germany, Dresden
Universitätsklinikum Carl Gustav Carus Dresden
Dini, Giorgio
Italy, Genoa
Istituto Giannina Gaslini
Sureda Balari, Anna Maria
Spain, Barcelona
Hospital de la Santa Creu I Sant Pau
Schmitz, Norbert
Germany, Hamburg
Asklepios Klinik St. Georg
Statistics
Citations: 72
Authors: 16
Affiliations: 14
Identifiers
Doi:
10.1182/blood-2008-11-189399
ISSN:
00064971
Research Areas
Maternal And Child Health